GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (FRA:RN3N) » Definitions » Cyclically Adjusted PB Ratio

Arena Pharmaceuticals (FRA:RN3N) Cyclically Adjusted PB Ratio : (As of May. 21, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Arena Pharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Arena Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Arena Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arena Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Arena Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Arena Pharmaceuticals Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Arena Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Arena Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arena Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arena Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Arena Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Arena Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Arena Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2021 is calculated as:

For example, Arena Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2021 was:

Adj_Book=Book Value per Share/CPI of Dec. 2021 (Change)*Current CPI (Dec. 2021)
=9.678/117.6295*117.6295
=9.678

Current CPI (Dec. 2021) = 117.6295.

Arena Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201203 1.880 96.783 2.285
201206 3.962 96.819 4.814
201209 4.188 97.633 5.046
201212 3.456 96.871 4.197
201303 2.852 98.209 3.416
201306 4.339 98.518 5.181
201309 3.835 98.790 4.566
201312 3.064 98.326 3.666
201403 4.152 99.695 4.899
201406 3.443 100.560 4.027
201409 2.689 100.428 3.150
201412 1.743 99.070 2.070
201503 4.923 99.621 5.813
201506 3.949 100.684 4.614
201509 3.020 100.392 3.539
201512 2.024 99.792 2.386
201603 1.388 100.470 1.625
201606 0.496 101.688 0.574
201609 0.122 101.861 0.141
201612 1.554 101.863 1.795
201703 1.004 102.862 1.148
201706 2.318 103.349 2.638
201709 4.678 104.136 5.284
201712 4.456 104.011 5.039
201803 9.629 105.290 10.758
201806 9.703 106.317 10.735
201809 9.217 106.507 10.180
201812 10.782 105.998 11.965
201903 22.209 107.251 24.358
201906 21.342 108.070 23.230
201909 20.888 108.329 22.681
201912 19.221 108.420 20.854
202003 17.786 108.902 19.211
202006 19.166 108.767 20.728
202009 17.112 109.815 18.330
202012 15.153 109.897 16.219
202103 15.049 111.754 15.840
202106 13.203 114.631 13.548
202109 11.107 115.734 11.289
202112 9.678 117.630 9.678

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Arena Pharmaceuticals  (FRA:RN3N) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Arena Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Arena Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Arena Pharmaceuticals (FRA:RN3N) Business Description

Traded in Other Exchanges
N/A
Address
136 Heber Avenue, Suite 204, Park City, UT, USA, 84060
Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Arena Pharmaceuticals (FRA:RN3N) Headlines

No Headlines